ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics. Their mission is to provide high-quality, reliable, and safe products for the treatment of immunodeficient patients at risk for infection and for other indications. ADMA leverages its expertise in plasma collection, fractionation, and purification to produce therapies like BIVIGAM®, ASCENIV™, and Nabi-HB®. The company operates its own FDA-licensed plasma collection facilities through its ADMA BioCenters subsidiary, ensuring control over its supply chain.
The Ramsey facility serves as the central hub for ADMA's corporate leadership, research and development, cGMP manufacturing, quality assurance, and commercial operations for its plasma-derived biologics.
The headquarters includes a state-of-the-art, FDA-licensed plasma fractionation and purification facility, advanced research and development laboratories, and modern corporate offices.
ADMA Biologics fosters a science-driven, patient-centric work culture. Employees often describe it as collaborative and innovative, with a strong emphasis on quality, compliance, and the mission to serve patients with rare diseases.
This integrated facility is crucial to ADMA's 'end-to-end' business model, enabling the company to control the entire production process from plasma collection (via its BioCenters) to the distribution of finished biologic products, ensuring quality and supply reliability.
ADMA Biologics primarily operates and markets its products within the United States. Its plasma collection network (ADMA BioCenters) and its advanced biopharmaceutical manufacturing facility are all U.S.-based. While its therapeutic products address conditions that affect patients globally, the company's current commercialization efforts and direct operational footprint are focused on the domestic U.S. market.
465 State Route 17
Ramsey
New Jersey
USA
Address: 5800 Park of Commerce Blvd NW, Boca Raton, Florida 33487
Manages and standardizes plasma collection operations, donor recruitment, and compliance across ADMA's network of plasma centers, ensuring a consistent and high-quality supply of human plasma, the critical raw material for its immunoglobulin therapies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ADMA' leadership includes:
ADMA has been backed by several prominent investors over the years, including:
ADMA Biologics has actively strengthened its executive leadership over the past year, notably with strategic appointments in Regulatory Affairs & Quality and Digital & Information roles to support its growth. There was also a key departure in a technical operations leadership position.
Discover the tools ADMA uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ADMA Biologics commonly uses the [first_initial][last]@[companydomain] email format. The primary domain observed in official communications is 'admabio.com'. This format is typical for many corporations and facilitates direct communication with company personnel.
[first_initial][last]@admabio.com
Format
jdoe@admabio.com
Example
75%
Success rate
Yahoo Finance (via PR Newswire) • May 8, 2024
ADMA Biologics announced record revenues of $81.8 million for Q1 2024, a 62% increase year-over-year. The company achieved its second consecutive quarter of positive net income and reiterated its full-year 2024 revenue guidance of $330 to $360 million, indicating strong commercial momentum....more
GlobeNewswire • April 1, 2024
ADMA Biologics received FDA approval for its Biologics License Application (BLA) supplement, enabling the use of Haemonetics' Persona technology for plasma pool collection. This approval is anticipated to enhance plasma collection efficiency, yield, and donor satisfaction at its ADMA BioCenters....more
GlobeNewswire • February 28, 2024
ADMA reported record revenues of $73.3M for Q4 2023 and $258.2M for full-year 2023. Significantly, the company achieved its first profitable quarter on a GAAP net income basis and positive adjusted EBITDA, marking a major financial turning point and demonstrating successful execution of its growth strategy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ADMA, are just a search away.